Oteseconazole is under clinical development by Mycovia Pharmaceuticals and currently in Phase I for Cryptococcal Meningitis. According to GlobalData, Phase I drugs for Cryptococcal Meningitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Oteseconazole LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oteseconazole overview

Oteseconazole (Vivjoa, Rebicon) is a  potent and selective anti fungal agent. It is formulated as hard gelatin capsules for oral route of administration, Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.   
Oteseconazole (VT-1161) is under development for the treatment of fungal diseases such as Coccidioidomycosis, cryptococcal meningitis, Rhizopus oryzae infection causes zygomycosis, onychomycosis and chronic mucocutaneous candidiasis. It is a small molecule. The drug candidate is administered through oral route as a tablet. It acts by targeting lanosterol 14-alpha-demethylase or CYP51. The drug candidate is based on Metallophile technology platform. It was also under development for the treatment of recurrent vulvovaginal candidiasis, athlete's foot (tinea pedis) and Coccidioidomycosis.

Mycovia Pharmaceuticals overview

Mycovia Pharmaceuticals (Mycoyia Pharmaceuticals), formerly known as Viamet Pharmaceuticals Inc, discovers and develops novel medicinal drugs based on metalloenzyme chemistry and biology technology platform. Its product portfolio includes clinical-stage compounds such as VT-1161, an oral inhibitor used for the treatment of onychomycosis and recurrent vulvovaginal candidiasis; VT-1129, an oral agent for the treatment of cryptococcal meningitis; VT-1598, an oral inhibitor to treat invasive fungal infections, including coccidioidomycosis. The company’s proprietary MIDAS technology enables to discover metalloenzyme inhibitors that target fungal CYP51 of both chronic and life threatening fungal infections. Mycoyia Pharmaceuticals is headquartered in Durham, North Carolina, the US.

For a complete picture of Oteseconazole’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.